Thiostrepton
(Synonyms: 硫链丝菌素) 目录号 : GC13002
An inhibitor of FoxM1
Cas No.:1393-48-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Thiazole antibiotic thiostrepton is an inhibitor of Forkhead box M1 (FOXM1), which effectively reduces cancer cell growth through downregulation of FOXM1. FOXM1 is a transcription factors that regulate expression of genes involved in maintenance of genomic stability and cell cycle progression.
In vitro: Thiostrepton inhibits the transcriptional activity and FOXM1 expression, and induces strong apoptosis in human cancer cells of different origin that correlates with suppression of FOXM1, including leukemia, neuroblastoma, liver cancer, melanoma and prostate cancer cells. Thiostrepton binds FOXM1 on the promoter site to inhibit transcriptional activity of FOXM1 through the FOXM1 autoregulation mechanism [1].
In vivo: Thiostrepton suppressed tumor growth in a human breast cancer xenograft model. Treatment with developed micelle-thiostrepton nanoparticles decreased xenograft tumor growth induced by the human MDA-MB-231 breast and HepG2 liver cancer cell lines. These apoptosis activities in drug-treated tumors were correlated with in vivo suppression of oncogenic FOXM1 [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Gartel AL. Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors. Scientifica (Cairo). 2014;2014:596528.
| Cas No. | 1393-48-2 | SDF | |
| 别名 | 硫链丝菌素 | ||
| 分子式 | C72H85N19O18S5 | 分子量 | 1664.89 |
| 溶解度 | 2mg/ml in DMSO, 25mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6006 mL | 3.0032 mL | 6.0064 mL |
| 5 mM | 0.1201 mL | 0.6006 mL | 1.2013 mL |
| 10 mM | 0.0601 mL | 0.3003 mL | 0.6006 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。